Product-liability insurers and reinsurers

"Which GLP-1 drugs gained new evidence of pancreatitis in the last 90 days, and did any foreign regulator act first?"

What comes back: an Emerging Evidence watch list, with foreign warnings and their dates. On the Watch lists page, enter a Drug or a Condition, a "Side effect (optional)" and a "Look back" window, then press Start watching. Each check compares the result with the previous one and adds one alert listing the evidence added or removed (a new reporting signal, a new study, a regulator acting abroad, a label change), each linked to its source. The first check sets the baseline.

"Surgical mesh migration: what device recalls and adverse event signals exist?"

What comes back: "FDA's recall search returned 150 recall product records for surgical polymeric mesh and seven related mesh categories". The device history card for hernia and abdominal-wall mesh lists up to 60 events by date and class, grouping the products under each recall, so the card is a window onto the record and not a total. It gives the firm's stated reason, the products affected and a link to the FDA record for each. A migration signal needs one product code, so the answer asks which one to check.

"Is there a disproportionality signal for gastroparesis with semaglutide? Show how it developed over time."

What comes back: "The cumulative PRR first met the stated signal rule on Sep 30, 2018, and was 78.9 by 2026Q2, based on 2,715 non-lawyer reports". Exposure sits under the chart: reports and claims in separate columns by year, with their ratio, from Medicare Part D (2018: 60,478 claims; 2024: 11,876,226) and, separately, from Medicaid. The ratio divides all FAERS reports in the series by the Part D claims, so it is an unmatched descriptive ratio, and the card states that it "is a reporting rate, not an incidence."

"Who has held the NDA for Zofran (ondansetron), and what FDA actions were taken on it?"

What comes back: each brand application with its holders and their dates, from FDA letters and Orange Book editions: GlaxoSmithKline last observed as holder on 18 Sep 2014; Novartis first observed on 31 Dec 2016 (it took over between 18 Sep 2014 and 31 Dec 2016) and last observed on 20 Oct 2021; Sandoz first observed on 2 Jun 2025. The answer adds the FDA safety-related labeling actions of 20 Oct 2021 and 2 Jun 2025, and states its limit: "The holder dates reflect the FDA letters and Orange Book editions available here, not a complete ownership-transfer history."